Where can I find news about NVS?

The latest headlines, third-party analysis, and SEC filings for Novartis AG (NVS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are NVS's SEC filings?

Novartis AG (NVS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are NVS's earnings call transcripts?

Full earnings call transcripts for Novartis AG (NVS), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

NVS

Novartis AG

NYSE·Drug Manufacturers, General · Healthcare

$153.53$2.41+1.59%

Market cap$291.82B·Oct 26 3:16 PM EDT

News & Analysis

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis (NYSE: NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory filings are underway, with a U.S. submission expected by the end of the year using
defenseworld.netOct 25, 2026 · 5:06 AM
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript
seekingalpha.comOct 24, 2026 · 12:37 AM
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies.
marketbeat.comOct 23, 2026 · 10:02 PM
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
reuters.comOct 23, 2026 · 1:51 PM
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
reuters.comOct 23, 2026 · 7:31 AM
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Novartis (NVS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zacks.comOct 22, 2026 · 10:15 AM
Novartis: The Sell-Off Creates An Attractive Entry Point
On October 27, Novartis will report its results for the third quarter. As a reminder, its Q2 revenue rose 10.6% quarter-over-quarter to $14.95 billion, primarily due to the strong performance of the oncology portfolio and Cosentyx. On September 18, 2026, the EMA's CHMP adopted a positive opinion recommending approval of Cosentyx for patients suffering from polymyalgia rheumatica.
seekingalpha.comOct 19, 2026 · 10:00 AM
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
reuters.comOct 16, 2026 · 1:35 PM

SEC Filings

6-K
Sep 8, 2026View on SEC
6-K
Sep 4, 2026View on SEC
6-K
Sep 1, 2026View on SEC
6-K
Jul 21, 2026View on SEC
6-K
Jun 11, 2026View on SEC
6-K
Apr 28, 2026View on SEC

Frequently Asked Questions About NVS

Where can I find news about NVS?: The latest headlines, third-party analysis, and SEC filings for Novartis AG (NVS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are NVS's SEC filings?: Novartis AG (NVS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are NVS's earnings call transcripts?: Full earnings call transcripts for Novartis AG (NVS), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

Novartis AG

Frequently Asked Questions About NVS

Novartis AG

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows

Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Novartis: The Sell-Off Creates An Attractive Entry Point

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Frequently Asked Questions About NVS

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows

Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Novartis: The Sell-Off Creates An Attractive Entry Point

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition